Multiple Starpharma 'partners' (and I use the term lightly) are stumping up cash for other biotechs and their drugs/treatments in their pipeline and in some instances taking over the whole company .... just nothing being sent Starpharma's way by our 'partners' after years of research with our tech
Shareholders are often told how strong our Merck and AstraZeneca partnerships 'supposedly' are when their big pharma logos are placed throughout multiple pages in Starpharma ASX announcements.......
........ and yet neither of those two big pharma companies have signed new 'actual' license deals or paid us any money for years and yet they are throwing billions at other biotechs across multiple deals ? Some examples in the last 6 months or so are below and the amounts aren't chicken feed - one Merck deal alone commits up to $22 billion and another for $1.3 billion was only announced last week
One might ask 'why is Starpharma always left out in the cold?' or 'why hasn't one of these cashed up big pharma companies (partners) made a takeover move while our market cap lingers under $60 million if the science is as good as many on here want us to believe ?'.
AstraZeneca:
https://www.astrazeneca.com/media-c...-across-oncology-and-autoimmune-diseases.html
26 December 2023
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
https://www.astrazeneca.com/media-c...tion-vaccine-with-positive-phase-ii-data.html
12 December 2023
AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data
Merck:
https://www.reuters.com/business/he...llaboration-sankyos-antibody-drug-2023-10-19/
October 21, 2023
Merck signs $5.5 billion deal with Daiichi for cancer therapy development
- Deal will see Merck pay $5.5 bln, and potentially up to $22 bln
- ADC drugs designed to target cancer
- Japanese firm has six ADC candidates in pipeline
- Daiichi Sankyo shares surge 12% in early trading
https://www.reuters.com/markets/dea...imal-healths-aqua-business-13-bln-2024-02-05/
February 7, 2024
Merck to buy Elanco's aqua health business for $1.3 billion
https://www.merck.com/news/merck-completes-acquisition-of-prometheus-biosciences-inc/
June 16, 2023
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
